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ABSTRACT 
There is an unmet need for predictive biomarkers of the clinical benefit of antiangiogenic drugs. The aim of the 
present study was to prospectively evaluate the value of 18F-FDG-PET/CT performed during and after 
preoperative chemoradiotherapy with bevacizumab for the prediction of complete pathologic tumor regression 
and survival in magnetic resonance imaging (MRI)-defined high-risk locally advanced rectal cancer (LARC) 
patients. 
Methods Sixty-one patients treated in a non-randomized phase II study (BRANCH) with concomitant or 
sequential (4 days before chemoradiotherapy) administration of bevacizumab with preoperative 
chemoradiotherapy were included. 18F-FDG PET/CT was performed at baseline, 11 days after the beginning of 
chemoradiotherapy (early) and before surgery (late). Metabolic changes were compared with pathological 
complete (TRG1) vs incomplete (TRG2-5) tumor regression, progression-free survival (PFS), cancer specific 
survival (CSS) and overall survival (OS). Receiver operating characteristic (ROC) curves were calculated for 
those 18F-FDG-PET/CT parameters that significantly correlated with TRG1. 
Results Early total lesion glycolysis (TLG-early) and its percent change compared to baseline (ΔTLG-early) 
could discriminate TRG1 from TRG2-5. Only ROC analysis of ΔTLG-early showed an area under curve (AUC) > 
0.7 (0.76), with an optimal cutoff at 59.5% (80% sensitivity, 71.4% specificity) for identifying TRG1. Late 
metabolic assessment could not discriminate between the two groups. After a median follow-up of 98 months 
(range 77–132) metabolic responders (ΔTLG-early ≥ 59.5%) demonstrated a significantly higher 10-year PFS 
(89.3% vs 63.6%, p=0.02) and CSS (92.9% vs 72.6%, p=0.04) compared to incomplete metabolic responders. 
Conclusion Our results suggest that early metabolic response can act as a surrogate marker of the benefit of 
antiangiogenic therapy and provide further support for the use of early 18F-FDG-PET/CT evaluation to predict 
pathological response and survival in the preoperative treatment of patients with LARC. ΔTLG-early showed the 
best accuracy in predicting TRG and may be particularly useful in guiding treatment modifying decisions during 
preoperative chemoradiotherapy based on expected response. 
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INTRODUCTION 
Although, preoperative multimodality treatment advances have remarkably improved the outcomes of patients 
with locally advanced rectal cancer (LARC), there is still a clear need to optimize the management of these 
patients (1). The evidence that LARC represents a widely heterogeneous group of tumors with different 
prognostic features has prompted to pursue different risk-adapted treatment strategies in order to maximize 
benefit and minimize toxicity of treatment (1). 
Moreover, the increased awareness of negative effects on quality of life consequent to long-term morbidity of 
surgery (2) and the excellent outcomes associated with pathological complete response, have led to explore 
organ preservation strategies in selected patients with good response to neoadjuvant treatment (3).  
An intriguing conservative strategy that has become very popular recently is the “watch and wait” approach. This 
strategy omits surgery when a complete clinical response is obtained after preoperative treatment and provides 
“true” organ-sparing. However, concerns about the safety of this approach have been raised (2) considering that 
the current selection criteria rely exclusively on clinical assessment, which may be of limited accuracy after 
preoperative treatment (4,5). A promising role in the prediction of pathological tumor response has been 
advocated for metabolic imaging with 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-
PET) in LARC (6). Interestingly, growing evidence has shown that this functional imaging is able to reliably 
predict treatment response early, during preoperative treatment (7). Our group has recently reported that early 
metabolic change, accurately predicts pathological response and long-term outcome in LARC (8). The early 
identification of response has great clinical importance because it offers the opportunity for response-guided 
tailoring of preoperative treatment and subsequent surgery, allowing to refer non-responders to alternative 
treatment and good responders to a conservative surgical approach.  
We have recently reported the final results of a non-randomized phase 2 study, to assess the safety and efficacy 
of traditional “concomitant” versus experimental “sequential” (4 days before chemoradiotherapy) administration 
of bevacizumab, with preoperative chemotherapy, in magnetic resonance imaging (MRI)-defined high-risk LARC 
patients (BRANCH Trial) (9). The primary endpoint, pathological complete tumor regression (TRG1), was 
reached with the sequential schedule and the final TRG1 rate was 50% (95% CI 35%–65%). Since there is an 
unmet need for predictive biomarkers of the clinical benefit of antiangiogenic drugs, we have also explored the 
potential predictive role of early metabolic response.  
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MATERIALS AND METHODS 
Patient Selection 
 
PET imaging was performed as part of the phase II BRANCH trial (Clinicaltrials.gov number: NCT01481545) 
evaluating preoperative chemoradiotherapy in patients with pathologically confirmed untreated MRI-defined 
high-risk LARC as reported previously (9). These included patients with tumors with concomitant resectable 
distant metastases and/or T4 features, any T N1-2 tumors and T3N0 tumors located in the lower third of the 
rectum and/or whose radial margin was ≤ 5 mm from the mesorectal fascia (MRF). The study was conducted 
under a protocol approved by the local Ethics Committee and was in accordance with the Helsinki Declaration. 
Treatment and Follow-up 
Chemotherapy, given during radiotherapy (45 Gy over 5 weeks), consisted of three biweekly cycles of infusional 
oxaliplatin (100 mg/m2) followed by raltitrexed (2.5 mg/m2) on day 1, levo-folinic acid (250 mg/m2) and a bolus 
of 5-fluorouracil (800 mg/m2) on day 2. Bevacizumab 5 mg/kg was administered 2 weeks before the start of 
chemoradiotherapy and on day 1 of each cycle (concomitant schedule) or 4 days prior to the first and second 
cycle of chemotherapy (sequential schedule). Two additional cycles of chemotherapy with one bevacizumab 
infusion were allowed after the end of chemoradiotherapy in patients with distant metastases. Total mesorectal 
excision (TME) was planned 8 weeks after the last day of radiotherapy. Four months of post-operative adjuvant 
FOLFOX4 regimen was planned only in patients with ypN+ or circumferential resection margin (CRM) ≤ 1 mm on 
pathology or for patients having distant metastases at baseline resected with R0/R1 status. Clinical examination, 
CEA serum levels, whole body CT and pelvic MRI, were performed every 4 months for the first 2 years of follow 
up, every 6 months for the next 3 years and annually thereafter. 
 
Pathological Analysis 
The surgical specimens were evaluated and scored according to the Mandard score (10), by two experienced 
pathologists who were unaware of PET findings. In case of discrepancy between the two pathologists, the worse 
TRG score was assigned. Based on these findings, patients were classified as pathological tumor complete 
responders (TRG1) or incomplete responders (TRG2-5).  
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18F-FDG-PET/CT Analysis 
18F-FDG-PET/computer tomography (18F-FDG-PET/CT) imaging was performed before (baseline), 11 days after 
starting chemoradiotherapy (early) and within one week prior to surgical resection (late).  
Patients, fasted for at least 6 h with blood glucose levels below 150 mg/dL, were administered 300-400 MBq of 
18F-FDG and scanning was started 60 min after injection. A General Electric Discovery DST-600 scanner (GE 
Healthcare, Milwaukee, WI, USA) routinely subject to daily and periodical quality control according to EANM 
guidelines (11) was utilized for scanning (3 min per bed position emission). CT based attenuation corrected 
images were reconstructed with the ordered subsets expectation maximization (OSEM) algorithm (2 iterations, 
16 subsets). Emission data were corrected for decay, dead time and random coincidences. Data were 
normalized for injected dose and patient body weight. Image analysis was performed in all cases with the same 
semi-automatic region-of-interest (ROI) drawing software package where a three-dimensional region was drawn 
around the area of increased uptake. Threshold values were adjusted in order to encompass the area of 
increased uptake visually. For each tumor volume, the following parameters were calculated: a) SUV = 
(measured activity concentration [Bq/mL])/(injected activity [Bq]/body weight [kg] 1000); b) SUV-max= the 
maximum pixel value measured in the visualized lesion; c) SUV-mean= the average SUV values in the ROIs; d) 
TLG (Total Lesion Glycolysis)= SUV-mean x metabolic tumor volume (mm3). Metabolic response was calculated 
by measuring early and late changes relative to baseline. Thus for all indicators a Δ value for early and late 
studies was calculated as follows [(baseline value – early or late value)/baseline value) × 100]. Correlations 
between these changes (Δ-early or Δ-late) and pathological tumor responses were determined.  
Statistical Analysis 
The primary end point of the BRANCH trial was the rate of TRG1 and the sample size was established applying 
Simon’s two-stage design as previously reported in details (9). The study also included biomarker studies and 
among these the predictive role of early metabolic response as assessed by 18F-FDG-PET/CT as a prospective 
secondary endpoint. All quantitative values have been expressed as medians and ranges (minimum and 
maximum) and proportions with their 95% confidence interval (CI). Receiver operating characteristic (ROC) 
curves were calculated for the 18F-FDG-PET/CT parameters that were found to be significantly correlated with 
TRG1. The area under the curve (AUC) was used to assess accuracy. Only when a test reported an AUC > 0.7 
the maximum product of sensitivity and specificity was chosen as the best cut-off value of the parameter for the 
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prediction of TRG1. To evaluate the independence of the cut-off value in predicting TRG1 a multivariate analysis 
was performed with the most relevant clinical variables: age, gender, Eastern Cooperative Oncology Group 
(ECOG) performance status (0 vs. 1 or 2), Gunderson risk (12), distance from the anal verge (≤ 5 cm vs. > 5 
cm), distance from the MRF (≤ 2 mm vs. > 2 mm) and baseline CEA serum level (≤ 5 UI/L vs. > 5 UI/L). The 
odds ratio (OR) and 95 % CI were used to report the results. Progression-free survival (PFS) was defined as the 
time from initial treatment until tumor progression or relapse, death for any cause or last follow-up. Patients who 
were progression free at the closeout date had their time to progression censored to that date. Overall survival 
(OS) was defined as the time from initial treatment until death for any cause or to last follow-up. Cancer-specific 
survival (CSS) was defined as the time to cancer related death or to the last follow-up. Patients who were alive 
at the closeout date had their OS and CSS censored to that date.  
PFS, OS and CSS rates were estimated with their 95% CI using the Kaplan-Meier method and compared with 
the log-rank test. For survival analysis, in the eight patients with distant metastases, metabolic response of 
metastatic lesions according to previously described criteria (TLG reduction >50%) (13)) was also taken into 
account when defining patients as responders and incomplete responders based on 18F-FDG-PET/CT. 
The Cox regression model was used to assess the role of the cut-off value of 18F-FDG-PET/CT parameters in 
predicting PFS, OS and CSS. Hazard ratios (HR) were derived from Cox regression analysis. A univariate 
analysis assessed the correlation of pre- and post-surgical characteristics with PFS, OS and CSS. Multivariate 
analysis was performed according to a backward elimination of factors showing a p < 0.10 in the univariate 
analysis. In all statistical tests a p value < .05 was considered significant. All statistical analyses were performed 
using SPSS software (version 22, SPSS Inc.).  
 
RESULTS 
Patient Characteristics and Pathology Results 
A total of 61 consecutive patients, including eight patients with concomitant distant resectable metastases (5 
liver, 1 lung and 2 lymph node metastases) were evaluated with 18F-FDG-PET/CT. One patient refused surgery 
and of the remaining patients, 25 showed a TRG1 response, while 35 were TRG2-4. The median interval 
between the end of chemoradiotherapy and TME was 9 weeks for both TRG1 (range, 7–13) and TRG2-4 (range, 
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7–15). No significant differences in baseline disease characteristics were observed between TRG1 and TRG2-4 
(Table 1). 
 
Relationship between 18F-FDG-PET/CT Parameters and Pathological Response  
The median times between the start of preoperative chemoradiotherapy and the early PET scan and between 
the completion of chemoradiotherapy and the late PET were, respectively, 11 days for both TRG1 (range 9 – 21 
days) and TRG2-4 (range 9 – 14 days) and 59 days (range 50 – 89 days) for TRG1 and 58 days (range 43 – 96 
days) for TRG2-4. Among the 18F-FDG-PET/CT parameters analyzed, early change of SUV-max showed 
borderline predictive value for response, but a significant differences between TRG1 and TRG2-4 were seen 
only in the early PET assessment, for day 11 TLG and for ΔTLG-early (Table 2). However, the AUC for day 11 
TLG was not sufficiently accurate to establish an optimal cut-off (AUC 0.68, 95% CI 0.53-0.82, Supplemental 
Fig.1), whereas for ΔTLG-early the AUC was 0.76, (95% CI 0.64-0.89, p=0.001) with an optimal cut-off of 59.5% 
(80% sensitivity, 71.4% specificity) in identifying TRG1 (Fig.1). In Figs. 2 and 3 two representative cases of 
metabolic response in pathological complete and incomplete responders, are shown. Among the 30 patients with 
a ΔTLG-early ≥ 59.5%, 20 (67%) were classified as TRG1, 9 (30%) as TRG2 and 1 (3%) as TRG3, positive 
predictive value of 67% (PPV, probability of correct identification of TRG1). On the contrary, among the 
remaining 30 patients with a ΔTLG-early < 59.5%, only 5 (17%) were TRG1, 13 (43%) were TRG2 and 12 (40%) 
were TRG3-4, negative predictive value 83% (NPV, probability of correct identification of TRG2-4). It should be 
noted that two false-negative subjects (TRG1 with ΔTLG-early < 59.5%), received two additional cycles of 
chemotherapy after the end of chemoradiotherapy and prior to surgery because they had distant metastases. 
Interestingly, the relationship between ΔTLG and TRG observed early was not maintained in the late evaluation 
(Table 2). Moreover, the pathological primary tumor stage was ypT0-2 in all but one (97%) patient with ΔTLG-
early ≥ 59.5% (henceforth referred to as “metabolic responders”) and in 23 of 30 (77%) with ΔTLG-early < 59.5% 
(incomplete metabolic responders). Lymph node involvement was found in 7 (23%) metabolic responders and in 
11 (37%) incomplete metabolic responders.  
Overall, pathological complete responses were observed in 16 of 30 (53%) metabolic responders and in only 5 
of 30 (17%) incomplete metabolic responders. Primary tumor resection was complete in all metabolic 
by Cambridge University Medical Library on October 18, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
PET is an early predictor of bevacizumabPag. 8 
 
responders, whereas a positive CRM was found in two incomplete metabolic responder patients. (Supplemental 
Table 1).  
Multivariate analysis showed a strong and independent correlation of ΔTLG-early in predicting TRG1 (Table 3).  
 
Metabolic Changes and Long-term Outcomes  
With a median follow-up time of 98 months (range 77–132) 15 patients showed cancer progression (1 local 
recurrence; 6 local and distant recurrence; 4 distant recurrence; 4 progression of distant metastases) and 12 
patients had died at the time of analysis. The overall estimated 10-year PFS, OS and CSS were 75.4% (95% CI 
63.3%-84.5%), 78.7% (95% CI 66.9%–87.1%), and 82.0% (95% CI 70.5%-89.6%), respectively (Supplemental 
Fig. 2).  
Survival analysis was performed to compare metabolic responders and incomplete responders. Two of the eight 
patients with distant metastases at enrollment showed discordant metabolic response between the primary 
tumor, showing marked metabolic response (ΔTLG-early 71% and 72%), and the metastatic lesions, that did not 
show significant metabolic response (TLG reduction <50%). These patients were classified as incomplete 
metabolic responders. In the remaining 6 patients metabolic response of the primary tumor (2 responders and 4 
incomplete responders), was not affected by metastatic lesions.  
Only 5 (18%) out of 28 metabolic responder patients received adjuvant chemotherapy; in 3 patients (11%) a 
recurrence occurred. On the contrary, 13 out of 33 (39%) incomplete metabolic responders (including the patient 
who refused surgery), received adjuvant chemotherapy; in 12 (36%) patients, recurrence or cancer progression 
was documented. Metabolic responders had a significantly longer PFS compared to incomplete responders (10-
year PFS 89.3%, 95% CI 72.8%-96.3%, vs 63.6%, 95% CI 46.6%–77.8%, log-rank test, p=0.02, Fig. 4). In the 
univariate analysis, only ΔTLG-early and ypTNM categories showed a significant association with PFS 
(HR=0.26, p=0.02 and HR=0.15, p=0.04, respectively, Table 4). A clear trend toward reduced risk of recurrence 
or cancer progression was observed for the TRG category. At multivariate analysis, none of these factors 
showed prognostic significance (Table 4). In relation to OS, 3 metabolic responders (11%) and 10 incomplete 
metabolic responders (30%) died and all but two deaths, one for each subgroup, were cancer related. Metabolic 
responders had a longer OS, although this difference was not statistically significant (10-year OS 89.3%, 95% CI 
72.8%-96.3%, vs 69.3%, 95% CI 52.7%–82.6%, log-rank test, p=0.06, Supplemental Fig. 3). However, metabolic 
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responders showed significantly longer CSS compared to incomplete responders, (10-year CSS 92.9% 95% CI 
77.4%-98% vs 72.6% 95 % CI 55.8%-84.9%, log-rank test, p=0.04, Fig. 4). In the univariate analysis only ΔTLG-
early showed a significant association with CSS (HR=0.23, p= 0.04, Table 4). At multivariate analysis, no factor 
showed prognostic significance. 
 
Metabolic Changes and Bevacizumab Scheduling 
The primary endpoint of the BRANCH study was the rate of TRG1. This was reached only using the sequential-
schedule of bevacizumab (TRG1 rate 50%, 95% CI 35%–65%). On the contrary, for the concomitant-schedule 
accrual was stopped early since the number of TRG1 (2 out of 16 patients) was statistically inconsistent with the 
preplanned first-stage analysis. In line with these results, we observed a significant difference in ΔTLG-early 
between the two different bevacizumab schedules (concomitant schedule, median 35%, range -129% to 83% vs 
sequential schedule, median 68%, range -31% to 90%; p= 0.0022, Fig. 5). On the contrary, no differences were 
observed in ΔTLG-late values  (concomitant schedule, median 86%, range -24% to 100% vs sequential 
schedule, median 91%, range -4% to 100%; p = 0.39, Fig 5).  
 
DISCUSSION 
This prospective study corroborates our previous evidence that early metabolic change accurately predicts 
pathological response and long-term outcome in LARC, showing a greater accuracy compared to late 
assessment (8). We found that only early metabolic response to preoperative chemoradiotherapy can 
discriminate LARC patients with TRG1 from those with TRG2-4 response. Looking for convenient parameters, 
we found that only ΔTLG-early showed an accurate AUC of 0.76 at ROC analysis, with an optimal cut-off of 
59.5% to distinguish TRG1 from TRG2-4. Moreover, among pre-surgical parameters only ΔTLG-early showed a 
strong and independent correlation in predicting TRG1 in the multivariate analysis. In addition, the PPV was 
67%, while the NPV was 83%. It is important to once again note that two false-negative subjects received two 
additional cycles of chemotherapy in the waiting period because they had distant metastases, highlighting the 
potential value of intensifying treatment in selected non-responding patients. Importantly, we showed that the 
relationship between ΔTLG and TRG observed early is lost in the late evaluation. Similarly, the borderline 
predictive value for response given by the more traditionally utilized SUV-max measurements is lost in the late 
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assessment. It should be noted that in the present study we used TRG1 instead of TRG1-2 as the reference for 
the evaluation of the predictive value of metabolic response. Most studies in this setting, as well as our previous 
experience, address major pathological response (TRG1-2). We confirm the difficulties of 18F-FDG-PET/CT in 
distinguishing between TRG1 and TRG2 given the very low spatial resolution and the very subtle differences at 
the cellular level (14,15). Indeed, among the patients with a ΔTLG-early ≥ 59.5% there were 9 patients (30%) 
with TRG2 and overall all but one patient (97%) were classified as TRG1-2 and pT0-2. On the contrary, only 5 
patients with TRG1 were wrongly classified as non-responders. In this group, 2 patients had received additional 
chemotherapy as reported above, leading to speculate that TRG1 may have been a consequence of additional 
chemotherapy and that 18F-FDG-PET/CT could allow clinicians to modify/intensify treatment based on PET 
findings. However, the low PPV for identifying TRG1 suggests the need to combine early 18F-FDG-PET 
assessment with other imaging modalities at different time points, such as DW-MRI or DCE-MRI, to improve the 
selection of patients for organ-preserving strategies (16,17). It is interesting to note that our data are consistent 
with another recent series (18) in which early reduction of SUV-max was the only parameter used to discriminate 
TRG1 from TRG2-5 although long-term outcome was not reported. In this regard, our findings support the use of 
TLG as a better composite parameter accounting for tracer avidity and metabolic tumor volume for this type of 
assessment as observed by several authors (19,20). 
A point of strength of this study is the long- term follow-up (median 98 months, minimum 77 months) which is 
hardly ever seen in other studies on this matter. Metabolic responder patients showed significantly higher 10-
year PFS probability (89.3%) compared to incomplete responders (63.6%), with a 74% reduction in risk of 
recurrence. Of note, none of the other pre-surgical parameters showed a significant association with PFS in the 
univariate analysis, while of the post-surgical factors only ypTNM was statistically correlated to PFS. 
Furthermore, metabolic responders show better 10-year OS (89.3% vs 69.3%), although this difference was not 
statistically significant, and significantly improved 10-year CSS (92.9%) compared to incomplete responders 
(72.6%), with a 77% reduction of the risk of cancer death. Overall, these results confirm the prognostic value of 
early metabolic response. However, the low number of events (recurrence, cancer progression or cancer death) 
limit the statistical power of the analysis for this as well as other prognostic factors in the multivariate analysis. 
The correlation between the early 18F-FDG-PET changes and long-term outcomes may also be particularly 
helpful in selecting patients for adjuvant treatment, in light of the debate between pros and cons of adjuvant 
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treatment following preoperative chemotherapy in LARC (21). In this regard, early metabolic response showed a 
significant ability to predict outcome despite a lower percentage of patients (18% vs 39%) receiving adjuvant 
treatment in our series. 
Finally we would like point out that, to the best of our knowledge, this is the first prospective study indicating a 
relevance of the use of early 18F-FDG-PET in the prediction of pathologic response and outcome in LARC 
patients treated with a chemoradiotherapy regimen with bevacizumab. In this setting, early metabolic 
assessment allowed a higher rate of prediction of TRG1 in the sequential compared to the standard concomitant 
bevacizumab administration scheme. Again, this capability was lost in the late metabolic assessment. These 
findings highlight the importance of assessing early functional changes compared to conventional RECIST 
criteria which are inadequate in addressing early changes. Early PET response may provide the sought after 
and as of yet undefined functional biomarker for response or resistance to antiangiogenic therapy (22,23). 
 
CONCLUSIONS 
The results of this study provide further support for the use of early PET response assessment as a clinical tool 
in management of patients with LARC, showing that ΔTLG-early can be utilized to predict pathological response 
and outcome. Our results show that early 18F-FDG-PET/CT could be particularly useful for identifying early 
incomplete pathological response, allowing clinicians to modify/intensify the treatment approach through 
radiotherapy dose escalation or additional chemotherapy in the waiting period. At the same time, early 
identification of patients likely to achieve complete pathologic response could complement morphological 
imaging findings and allow better selection of patients for organ-preserving strategies. Interestingly our results 
also indicate the potential of early 18F-FDG-PET/CT as a surrogate marker of the benefit of antiangiogenic 
therapy. These hypothesis generating findings warrant further evaluation in larger properly powered, and 
possibly multicenter studies to validate this approach. 
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FIGURE LEGENDS 
 
 
Figure 1 ROC curve for ΔTLG-early. The curve shows the accuracy of using ΔTLG-early (AUC 0.76, 95% CI 
0.64-0.89; p=0.001), with a cut-off ≥ 59.5% (80% sensitivity, 71.4% specificity) for predicting TRG1 vs TRG2-
4.  
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Figure 2 18F-FDG FDG-PET/CT images in a patient with complete pathological response. (A) Baseline 18F-FDG 
uptake in a cT3 lesion (TLG 470.40). (B) Early significant decrease in tumor TLG (TLG 65.86; ΔTLG-early 86%). 
(C) Late near complete disappearance of the tumor (TLG 14.11; ΔTLG-late 97%). Pathological analysis showed 
complete tumor regression (ypT0 N0, TRG1). Neither local nor distant recurrence occurred during 83 months of 
follow-up. 
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Figure 3 18F-FDG FDG-PET/CT images in a patient with incomplete pathological response. (A) Baseline 18F-
FDG uptake in a cT3 lesion (TLG 57.6). (B) Early slight decrease in tumor TLG (TLG 48.38; ΔTLG-early 16%). 
(C) Late near complete disappearance of the tumor (TLG 8.06; ΔTLG-late 86%). Pathological analysis showed 
incomplete pathological response (ypT3N1, TRG3). Pelvic recurrence and death occurred after 35 and 53 
months from initial treatment, respectively 
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Figure 4 Kaplan-Meier curves for Progression free survival (A) and Cancer specific survival (B) according to 
metabolic response 
   
A  B 
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Figure 5 Relationship between ΔTLG-early and ΔTLG-late with bevacizumab scheduling. 
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Table 1 Patient and tumor characteristics  
Characteristics All patients* n= 61 (%) 
TRG1 
n= 25 
TRG2-4 
n= 35 P† value 
Gender    0.40 
Male/female 37 (61)/24 (39) 16/9 20/15  
Age    0.40 
Median (range) 59 (43–74) 59 (47–74) 60 (43–69)  
ECOG performance status    0.20 
0 vs 1 or 2 30 (49)/31 (51) 10/15 20/15  
Gunderson risk    0.21 
Intermediate: T3 N0 4 (6) 0 4  
Moderately high: T3 N1/T4 N0 20 (33)/2 (3) 8/1 12/0  
High: T3 N2/T4 N1–2/anyTanyNM1 24 (39)/3 (5)/8 (13) 9/1/6 15/2/2  
Distance from the anal verge    0.34 
≤ 5 cm (low-lying tumor) 34 (56) 15 18  
> 5 cm (mid/upper tumor) 27 (44) 10 17  
Distance from the Mesorectal Fascia (MRF)    0.40 
≤ 2 mm 32 (52) 15 16  
> 2 mm 25 (41) 10 15  
Not evaluated‡ 4 (7) 0 4  
Baseline CEA serum level    0.60 
≤ 5 UI/L 38 (62) 16 22  
> 5 UI/L 23 (38) 9 13  
ECOG Eastern Cooperative Oncology Group 
*one patient with tumor T4N0 refused surgery; †Chi-square or Mann-Whitney test; ‡No MRI performed due to 
the presence of metal prosthesis 
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Table 2 FDG-PET/CT parameters in relation to TRG1 (tumor complete responders) and TRG2-4 (tumor 
incomplete responders)  
 
Parameters All patients* 
n= 61 (range) 
TRG 1 
n= 25 (range) 
TRG 2-4 
n= 35 (range) 
P† value 
Median SUVmax     
    Baseline 12.1 (2.7-49.5) 12.2 (3.6-49.5) 10.9 (2.7-27.2) 0.87 
    Day 11 (early) 8.3 (1-30.6) 8.2 (1-30.6) 8.6 (3.7-19.3) 0.26 
    Pre-surgery (late) 4 (0-14.1) 3.9 (0-10.3) 4.1 (0-14.1) 0.46 
    ΔSUV-early, % 27 (-243 to 73) 40 (-16 to 73) 24 (-243 to 73) 0.06 
    ΔSUV-late, % 66 (-83 to 100) 72 (-69 to 100) 66 (-83 to 100) 0.94 
Median SUVmean     
    Baseline 5.75 (1.6-13.9) 5.9 (1.7-11.2) 5.7 (1.6-13.9) 0.87 
    Day 11 (early)     4.8 (1.5-12) 4.7 (1.5-12) 4.9 (2.2-9.7) 0.38 
    Pre-surgery (late) 2.9 (0-7.9) 2.9 (0-5.7) 2.9 (0-7.9) 0.80 
    ΔSUV-early, % 19 (-123 to 61) 27 (-36 to 61) 15 (-123 to 59) 0.19 
    ΔSUV-late, %   56 (-125 to 100) 59 (-125 to 100)   56 (-80 to 100) 0.94 
Median TLG     
    Baseline 155.3 (13.4-980.4) 107.2 (13.4-980.4) 167 (36.9-572) 0.78 
    Day 11 (early) 65.2 (2.6-840.7) 41 (2.6-672) 82.4 (21.8-840.7) 0.02 
    Pre-surgery (late) 17.3 (0-193.9) 13.9 (0-193.9) 22.9 (0-153.8) 0.18 
    ΔTLG-early, % 58 (-129 to 90) 74 (-31 to 86) 42 (-129 to 90) 0.001 
    ΔTLG-late, % 90 (-24 to 100) 93 (-4 to 100) 86 (-24 to 100) 0.30 
*one patient with tumor T4N0 refused surgery; †Mann-Whitney test;  
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Table 3 Multivariate analysis for the identification of TRG1 
Variable Multivariate Analysis 
 OR 95% IC P 
value 
Sex 
(Male vs Female) 0.52 0.12-2.19 0.38 
Age 
(≤65 vs > 65) 0.66 0.15-2.79 0.57 
ECOG performance status 
(0 vs 1-2) 0.45 0.12-1.70 0.24 
Gunderson risk 
(Intermediate/Moderate vs High) 0.46 0.11-1.86 0.27 
Distance from the anal verge 
(> 5 cm vs ≤ 5 cm) 0.29 0.06-1.27 0.10 
Distance of Mesorectal Fascia 
(MRF) 
(> 2 mm vs ≤2 mm) 
1.34 0.32-5.59 0.68 
Baseline CEA serum level 
( ≤ 5 UI/L vs > 5 UI/L) 1.53 0.35-6.75 0.56 
ΔTLG-early % 
(≥ 59.5 vs < 59.5) 
10.86
4 
2.54-
46.34 0.001 
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Table 4 Univariate and multivariate analysis of prognostic factors for PFS and CSS 
 
 PFS CSS 
Variable Univariate Analysis Multivariate Analysis Univariate Analysis Multivariate Analysis 
Presurgical HR 95% IC P value HR 95% IC P value HR 95% IC P value HR 95% IC P value 
Sex 
(Male vs Female) 0.75 0.27 – 2.06 0.57    0.78 0.24 – 2.56 0.68    
Age 
(≤65 vs > 65) 0.85 0.31 – 2.36 0.76    1.23 0.37 – 4.02 0.73    
ECOG performance status 
(0 vs 1-2) 0.52 0.18 – 1-46 0.21    0.45 0.13 – 1.54 0.19    
Gunderson risk 
(Intermediate/Moderate vs 
High)  
0.68 0.23 – 2.01 0.49    0.50 0.13 – 1.89 0.29    
Distance from the anal verge  
(> 5 cm vs ≤ 5 cm) 0.41 0.13 – 1.28 0.11    0.50 0.13 – 1.96 0.20    
Distance of Mesorectal 
Fascia (MRF) 
(> 2 mm vs ≤2 mm) 
0.56 0.19 – 1.66 0.29    0.43 0.11 – 1.62 0.20    
Baseline CEA serum level 
( ≤ 5 UI/L vs > 5 UI/L) 0.70 0.25 – 1.9 0.47    1.05 0.31 – 3.60 0.93    
ΔTLG-early % 
(≥ 59.5 vs < 59.5) 0.26 0.07– 0.9 0.02 0.43 0.1 – 1.74 0.24 0.23 0.05 – 1.09 0.04 0.44 0.08 - 2.36 0.34 
Postsurgical             
TRG 
(1 vs 2-4 or M1) 0.25 0.05 – 1.13 0.05 1.07 0.13 – 8.8 0.94 0.17 0.02 – 1.39 0.06 0.27 0.03 - 2.53 0.25 
yTNM 
(T0N0M0 vs T1-4 and/or N+ 
or M1) 
0.15 0.02 – 1.19 0.04 0.22 0.01 – 3.62 0.29 0.24 0.03 – 1.91 0.14    
Analysis for yCRM was not done because only 2 cases had a margin positive (≤ 1 mm) 
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SUPPLEMENTARY MATERIAL 
 
 
 
Supplemental Figure 1 ROC curve for TLG Day 11. The curve shows the accuracy of using TLG Day 11 (AUC 
0.68, 95% CI 0.53-0.82; p=0.021) for predicting pathological tumor complete response (TRG1 vs TRG2-4). The 
optimal cut-off value was a TLG Day 11 of 42.3% (82.9% sensitivity, 56% specificity). 
  
by Cambridge University Medical Library on October 18, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
  
 
 
 
Supplemental Figure 2 Kaplan-Meier curves for Progression free survival (A), Overall survival (B) and Cancer 
specific survival (C). 
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Supplemental Figure 3 Kaplan-Meier curve for Overall survival according to metabolic response 
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 Supplemental Table 1 Pathological findings in relation to metabolic responder,  
Pathological Results* ΔTLG-early ≥ 59.5% 
n=30 
ΔTLG-early < 59.5% 
n=30  
p† value 
TRG1 20 5  
TRG2-4 10 25 0.000086 
ypT0N0 16 5  
ypT1-4 or N1-2  14 25 0.003 
ypT0-2 29 23  
ypT3-4 1 7 0.02 
ypN0 23 19  
ypN1-2 7 11 0.26 
yCRM+ 0 2  
yCRM- 30 28 0.15 
*one patient with tumor T4N0 refused surgery; †Chi-square test;  
yCRM+= circumferential resection margin ≤ 1 mm;  
yCRM-= circumferential resection margin > 1 mm;  
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 Supplemental Table 2 Univariate and multivariate analysis of prognostic factors for OS 
Variables Univariate Analysis Multivariate Analysis 
 HR 95% IC P value HR 95% IC P value 
Presurgical       
Sex  
(Male vs Female) 
1.02 0.33 – 3.11 0.97    
Age 
(≤65 vs > 65) 
0.88 0.29 – 2.62 0.81    
ECOG performance status  
(0 vs 1-2) 
0.68 0.23 – 2.04 0.49    
Gunderson risk 
(Intermediate/Moderate vs High)  
0.39 0.10 – 1.41 0.13    
Distance from the anal verge 
(> 5 cm vs ≤ 5 cm) 
0.51 0.16 – 1.68 0.26    
Distance of Mesorectal Fascia (MRF) 
(> 2 mm vs ≤2 mm) 
0.49 0.15 – 1.60 0.23    
Baseline CEA serum level 
( ≤ 5 UI/L vs > 5 UI/L) 
0.95 0.31 – 2.91 0.93    
ΔTLG-early % 
(≥ 59.5 vs < 59.5) 
0.31 0.09 – 1.15 0.06    
Postsurgical       
TRG 
(1 vs 2-4 or M1) 
0.31 0.07 – 1.44 0.11    
ypTNM 
(T0N0M0 vs T1-4 and/or N+ or M1) 
0.44 0.09 – 2.01 0.27    
Analysis for yCRM was not done because only 2 cases had a margin positive (≤ 1 mm) 
by Cambridge University Medical Library on October 18, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
Doi: 10.2967/jnumed.118.222604
Published online: March 15, 2019.
J Nucl Med. 
  
Paolo Muto, Gerardo Botti, Paolo Delrio and Secondo Lastoria
Vincenza Granata, Francesco Bianco, Carmela Romano, Francesca Di Gennaro, Alfredo Budillon, Antonella Petrillo, 
Antonio Avallone, Luigi Aloj, Biagio Pecori, Corradina Caraco, Alfonso De Stefano, Fabiana Tatangelo, Lucrezia Silvestro,
  
Rectal Cancer
Preoperative Radiochemotherapy with Bevacizumab in High Risk Locally Advanced 
F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival to18
 http://jnm.snmjournals.org/content/early/2019/03/14/jnumed.118.222604
This article and updated information are available at: 
  
 http://jnm.snmjournals.org/site/subscriptions/online.xhtml
Information about subscriptions to JNM can be found at: 
  
 http://jnm.snmjournals.org/site/misc/permission.xhtml
Information about reproducing figures, tables, or other portions of this article can be found online at: 
and the final, published version.
proofreading, and author review. This process may lead to differences between the accepted version of the manuscript 
 ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting,JNM
copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the 
. They have not beenJNM ahead of print articles have been peer reviewed and accepted for publication in JNM
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)
1850 Samuel Morse Drive, Reston, VA 20190.
SNMMI | Society of Nuclear Medicine and Molecular Imaging is published monthly.The Journal of Nuclear Medicine
© Copyright 2019 SNMMI; all rights reserved.
by Cambridge University Medical Library on October 18, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
